Skip to main content
. 2017 Jul 24;28(10):2420–2428. doi: 10.1093/annonc/mdx397

Table 1.

Patient characteristics at diagnosis

Variable TOTAL (n = 3055) ER < 1% (n = 932) 1% ≤ ER < 10% (n = 171) ER ≥ 10% (n = 1952) P value
Age, median (range), years 49 (19–83) 49 (22–83) 49 (19–77) 49 (22–83) 0.49
BMI, median (range), kg/m2 27.7 (14.5–65.9) 27.8 (14.5–56.4) 29 (17.7–31.3) 27.5 (15.5–66) 0.03
Race/ethnicity
 White 1915 (62.7) 565 (60.6) 97 (56.7) 1253 (64.2) <0.001
 Black 463 (15.2) 197 (21.1) 35 (20.5) 231 (11.8)
 Hispanic 483 (15.8) 128 (13.7) 25 (14.6) 330 (16.9)
 Asian/others 194 (6.4) 42 (4.5) 14 (8.2) 138 (7.1)
Menopausal status
 Premenopausal 1461 (47.8) 438 (47.2) 84 (49.1) 939 (48.4) 0.82
 Postmenopausal 1579 (51.7) 489 (52.8) 87 (50.9) 1003 (51.6)
 Unknown 15 (0.5) 0 (0) 0 (0) 0 (0)
Histology
 Ductal 2577 (84.4) 851 (91.3) 156 (91.2) 1570 (80.4) <0.001
 Lobular 231 (7.6) 15 (1.6) 2 (1.2) 214 (11)
 Others 215 (7.0) 40 (4.3) 7 (4.1) 168 (8.6)
 Unknown 32 (1.0) 26 (2.8) 6 (3.5) 0 (0)
Nuclear grade
 I/II 1163 (38.1) 91 (9.8) 19 (11.1) 1053 (53.9) <0.001
 III 1803 (59.0) 813 (87.2) 148 (86.5) 842 (43.1)
 Unknown 89 (2.9) 28 (3) 4 (2.3) 57 (2.9)
Clinical stage
 Stage II 1726 (56.5) 511 (54.8) 99 (57.9) 1116 (57.2) 0.46
 Stage III 1329 (43.5) 421 (45.2) 72 (42.1) 836 (42.8)
Neoadjuvant regimen
 A 292 (95.6) 70 (7.5) 9 (5.3) 213 (10.9) <0.001
 T 112 (36.7) 36 (3.9) 3 (1.8) 73 (3.7)
 A+T 2651 (86.8) 826 (88.6) 159 (93) 1666 (85.3)
ER, continuous, mean ± SD 51.88 ± 43.17
PR, categorical
 PR < 1% 1245 (40.8) 818 (87.8) 110 (64.3) 317 (16.2) <0.001
 1% ≤ PR < 10% 326 (10.7) 61 (6.5) 41 (24) 224 (11.5)
 PR ≥ 10% 1484 (48.6) 53 (5.7) 20 (11.7) 1411 (72.3)
PR, continuous, mean ± SD 31.6 ± 38.24 2.4 ± 11.3 4.6 ± 12.5 47.9 ± 38.5 <0.001
LVI
 Negative 2030 (66.4) 631 (67.7) 124 (72.5) 1275 (65.3) 0.005
 Positive 915 (30) 254 (27.3) 36 (21.1) 625 (32)
 Unknown 110 (3.6) 47 (5) 11 (6.4) 52 (2.7)
Adjuvant chemotherapy
 No 2594 (84.9) 770 (82.6) 155 (90.6) 1669 (85.5) 0.013
 Yes 461 (15.1) 162 (17.4) 16 (9.4) 283 (14.5)
Adjuvant hormonal therapy
 No 1020 (33.4) 846 (90.8) 128 (74.9) 46 (2.4) <0.001
 Yes 2035 (66.6) 86 (9.2) 43 (25.1) 1906 (97.6)
Adjuvant radiation
 No 636 (20.8) 237 (25.4) 50 (29.2) 349 (17.9) <0.001
 Yes 2419 (79.2) 659 (74.6) 121 (70.8) 1603 (82.1)
pCR
 No 2626 (86) 687 (73.7) 123 (71.9) 1816 (93) <0.001
 Yes 429 (14) 245 (26.3) 48 (28.1) 136 (7)

All data are no. of patients (%) unless noted otherwise.

ER, estrogen receptor; BMI, body mass index; A, anthracycline; T, taxane; SD, standard deviation; PR, progesterone receptor; LVI, lymphovascular invasion; pCR, pathological complete response.